Basilea Pharmaceutica AG (LON:0QNA)
London · Delayed Price · Currency is GBP · Price in CHF 58.53
+0.67 (1.16%)
Feb 12, 2026, 5:09 PM GMT
Basilea Pharmaceutica AG Employees
Basilea Pharmaceutica AG had 180 employees as of June 30, 2025. The number of employees increased by 16 or 9.76% since the number was reported on December 31, 2024.
Employees
180
Change
16
Growth
9.76%
Revenue / Employee
1.20M GBP
Profits / Employee
370.47K GBP
Market Cap
676.01M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 180 | 16 | 9.76% |
| Dec 31, 2024 | 164 | 17 | 11.56% |
| Dec 31, 2023 | 147 | 6 | 4.26% |
| Dec 31, 2022 | 141 | -13 | -8.44% |
| Dec 31, 2021 | 154 | -3 | -1.91% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,000 |
| Spire Healthcare Group | 15,703 |
| CVS Group | 8,850 |
| Advanced Medical Solutions Group | 1,500 |
| Oxford Nanopore Technologies | 1,325 |
Basilea Pharmaceutica AG News
- 4 weeks ago - Basilea Pharmaceutica Partners With INCATE To Advance Antibacterial And Antifungal Innovation - Nasdaq
- 5 weeks ago - Basilea provides portfolio update and outlook - GlobeNewsWire
- 5 weeks ago - Prokaryotics and Basilea enter collaboration to develop a novel broad-spectrum antifungal for severe invasive infections - PRNewsWire
- 2 months ago - Basilea partners with Phare Bio to deploy generative AI for antibiotic discovery - Seeking Alpha
- 2 months ago - Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic - GlobeNewsWire
- 2 months ago - Phare Bio and Basilea Announce Landmark Partnership to Develop Next-Generation Broad-Spectrum Antibiotic Using AI - Business Wire
- 3 months ago - Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea - GlobeNewsWire
- 5 months ago - Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam - GlobeNewsWire